Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Thomas J. Kipps, Graeme Fraser, Steven E. Coutre, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan M. O'Brien, Marie Sarah Dilhuydy, Peter Hillmen, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, Asher A. Chanan-Khan, Michelle Mahler, Mariya Salman, Karl Eckert, Isabelle G. Solman, Sriram BalasubramanianMei Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle F. James, Michael Hallek

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2019

    Fingerprint

Keywords

  • Prognostic factors
  • Risk factors
  • Small lymphocytic lymphoma
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kipps, T. J., Fraser, G., Coutre, S. E., Brown, J. R., Barrientos, J. C., Barr, P. M., Byrd, J. C., O'Brien, S. M., Dilhuydy, M. S., Hillmen, P., Jaeger, U., Moreno, C., Cramer, P., Stilgenbauer, S., Chanan-Khan, A. A., Mahler, M., Salman, M., Eckert, K., Solman, I. G., ... Hallek, M. (Accepted/In press). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2019.07.004